Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Mongodb Inc (MDB) Price & Performance

Inovio Pharmaceuticals IncTrade
Mongodb IncTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Mongodb Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Mongodb Inc trades at $438.95 (market cap $35.32B). The key difference: Mongodb Inc is far larger — about 449.6× Inovio Pharmaceuticals Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

INOMDB
Market Cap
$78.55M$35.32B
Sector
HealthTechnology
52-Week High
$2.87$440.25
52-Week Low
$0.66$204.37
Enterprise Value
$49.56M$32.93B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Mongodb Inc

MDB trades at $436.91, up 4.86% over the past day, with a bullish technical signal from moving averages and strong analyst sentiment. Revenue growth is robust, reaching $2.01B in 2025, though the company remains unprofitable with a net income margin of -1.12%. Recent earnings beats and an upcoming Q2 2026 report on September 1, 2026, highlight operational momentum amid high institutional interest.

The outlook is positive given consistent earnings outperformance and projected revenue growth to $2.6B in 2026. Risks include persistent losses, competitive pressures, and high valuation multiples. With 82% of analysts rating it a buy and a consensus price target of $404.30, the stock offers growth potential but requires monitoring of profitability trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About Mongodb Inc

Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.

Read more on MDB